---
title: "C&Y Pharmaceutical plans to launch a restricted stock incentive plan of no more than 9.15 million shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249582864.md"
description: "According to the Zhitong Finance APP, C&Y Pharmaceutical disclosed the draft of the 2025 Restricted Stock Incentive Plan, which proposes to grant a total of no more than 9.15 million restricted shares to the incentive recipients, accounting for 3.68% of the company's total share capital at the time of the announcement of this incentive plan draft. Among them, 7.95 million shares will be granted in the first grant, with a total of 171 incentive recipients, and the grant price (including reserves) is set at 5.60 yuan/share"
datetime: "2025-07-22T12:04:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249582864.md)
  - [en](https://longbridge.com/en/news/249582864.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249582864.md)
generator: "portal-rs"
---

# C&Y Pharmaceutical plans to launch a restricted stock incentive plan of no more than 9.15 million shares

According to the Zhitong Finance APP, C&Y Pharmaceutical (300254.SZ) has disclosed the draft of its 2025 restricted stock incentive plan, proposing to grant a total of no more than 9.15 million restricted shares to the incentive recipients, accounting for 3.68% of the company's total share capital at the time of the announcement of this incentive plan draft. Among them, 7.95 million shares will be granted in the first grant, with a total of 171 recipients for the first grant, and the grant price (including reserves) is set at 5.60 yuan/share

### Related Stocks

- [300254.CN](https://longbridge.com/en/quote/300254.CN.md)

## Related News & Research

- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)
- [Ata Turizm Discloses High Non-Compliant Income Under Participation Finance Rules](https://longbridge.com/en/news/296522750.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [TempraMed Announces Extension of Maccabi Healthcare Services Agreement | TMPTF Stock News](https://longbridge.com/en/news/296479419.md)
- [Earth Science Tech (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy](https://longbridge.com/en/news/296513181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**